- Company
- Dupixent to treat pediatric patients with atopic dermatitis
- by Eo, Yun-Ho Feb 22, 2021 06:17am
- The use of atopic dermatitis and asthma treatment Dupixent (dupilumab) could be expanding also in South Korea to be administered to children. A pharmaceutical industry source reported Sanofi Genzyme has submitted an indication expansion application last year on Dupixent to be indicated for a ‘treatment in pediatric patients aged six th
- Company
- Talks on expanding coverage on Tecentriq to start soon
- by Eo, Yun-Ho Feb 19, 2021 06:17am
- An immunotherapy Tecentriq (atezolizumab) is to face the first threshold to expand the National Health Insurance (NHI) reimbursement in treating patients with either triple-negative breast cancer (TNBC) or hepatocellular carcinoma. A pharmaceutical industry source reported the Health Insurance Review and Assessment Service (HIRA) Cancer D
- Company
- Meditoxin and Innotox back for sales, but what about safety?
- by Feb 19, 2021 06:17am
- Although the Ministry of Food and Drug Safety (MFDS) ordered a license revocation on Medytox’ botulinum toxin drugs, they would be back on the shelf and available for sales as the court halts the administrative action. The relevant industry insiders are pointing out MFDS should be more thorough with pre-sales lot release approval for the pe
- Company
- 19 Korean companies to challenge Entresto patent
- by Kim, Jin-Gu Feb 18, 2021 06:25am
- A series of South Korean pharmaceutical companies are challenging the patents on Novartis’ heart medicine Entresto (sacubitril, valsartan plus sodium salt hydrate complex). Starting with Elyson Pharm filing a patent trial as a first in last year, 18 other companies expressed their intention to release their generics early. According to
- Company
- SK Bioscience has signed a technology transfer contract
- by Kim, Jin-Gu Feb 18, 2021 06:24am
- SK Bioscience has secured the right to independently produce it in Korea by transferring the technology of Novavax vaccine. SK Bioscience announced on the 16th that it has licensed NVX-CoV2373 and signed a contract with the KCDA to supply 40 million doses of vaccine respectively. SK Bioscience announced on the 16th that it has signed a tec
- Company
- Does Propecia cause depression?
- by Eo, Yun-Ho Feb 17, 2021 05:40am
- It has already been reflected in the package insert such as Korea and Europe, and has not been directly proven to have a causal relationship. There was another controversy that the hair loss drug Propecia causes depression. Reuters reported on the 3rd (local time) of the lawsuit filed in the Brooklyn Federal Court of New York in connection
- Company
- SK Chemicals sells Janssen’s Ultracet
- by Lee, Seok-Jun Feb 17, 2021 05:39am
- SK Chemicals announced on the 15th that it has signed a domestic sales contract with Janssen Korea for the anti-pain inflammatory drug Ultracet (Acetaminophen/ Trimadol HCl). According to this agreement, SK Chemicals is in charge of Ultracet distribution ,domestic marketing and sales. Janssen Korea will be in charge of production. There
- Company
- RRMS, actively expanding coverage of drugs
- by Eo, Yun-Ho Feb 16, 2021 06:07am
- There is news of expanding coverage of oral RRMS (Relapsing-remitting multiple sclerosis) drugs. According to industry sources on the 8th, after Mavenclad (Cladribine, Merck) was listed in insurance benefits in the second half of last year, Sanofi Genzyme's primary drug Aubagio was expanded from February. In the case of Aubagio, additio
- Company
- Generics for Xeljanz are being approved one after another
- by Kim, Jin-Gu Feb 10, 2021 06:05am
- Generics for Xeljanz (Tofacitinib) are being approved one after another. After crystalline form patent was deleted from the list, it seems that domestic companies are competitively receiving generic licenses. According to the MFDS on the 9th, until this day, a total of 42 generics for Xeljanz have been licensed. Since Boryung's generic wa
- Company
- Despite COVID-19 and NDMA metformin prescription surges
- by Chon, Seung-Hyun Feb 10, 2021 06:04am
- Metformin-based antidiabetic drugs showed exceptional growth in the prescription drug market. Both metformin combination and single agent drugs expanded their prescription volume and maintained the credibility in the clinical scene, regardless of the novel coronavirus disease (COVID-19) outbreak and impurity contamination incident. On Feb. 9
